Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PPARs and diabetes-associated atherosclerosis.

A C Calkin1, K A Jandeleit-Dahm, E Sebekova

  • 1JDRF Centre for Diabetes Complications, Baker Heart Research Institute, Melbourne, Australia.

Current Pharmaceutical Design
|September 28, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inpatient Gastroenterology Workup Prior to Transesophageal Echocardiogram Is of Minimal Benefit to Patients.

Gastro hep advances·2024
Same author

Behavioral, metabolic, and lipidomic characterization of the 5xFADxTg30 mouse model of Alzheimer's disease.

iScience·2024
Same author

Urinary complement proteins and risk of end-stage renal disease: quantitative urinary proteomics in patients with type 2 diabetes and biopsy-proven diabetic nephropathy.

Journal of endocrinological investigation·2021
Same author

Benchmarking an 11-qubit quantum computer.

Nature communications·2019
Same author

Low daily MEWS scores as predictors of low-risk hospitalized patients.

QJM : monthly journal of the Association of Physicians·2019
Same author

Ultrafast creation of large Schrödinger cat states of an atom.

Nature communications·2017
Same journal

Fentanyl and its Analogs: A Medicinal Chemistry Perspective on Therapeutic Potential and Abuse Liability.

Current pharmaceutical design·2026
Same journal

Acne Vulgaris: Integrating Pathophysiology with Conventional, Herbal, and Nanocarrier-Based Therapeutic Strategies.

Current pharmaceutical design·2026
Same journal

Systems Pharmacology and Pharmaco-Transcriptomic Insights into Bauhinia variegata for Polycystic Ovary Syndrome Management.

Current pharmaceutical design·2026
Same journal

Curcumin and Cognitive Health: Insights from Randomized Controlled Trials.

Current pharmaceutical design·2026
Same journal

Inorganic Materials-integrated Porphyrin for Drug Delivery in Cancer Therapy: Promises, Challenges and Outlooks.

Current pharmaceutical design·2026
Same journal

Precision Nanotechnology in Oral Oncology: From Biomarker-Guided Targeting to AI-Driven Theranostics.

Current pharmaceutical design·2026
See all related articles

Peroxisome proliferator-activated receptor (PPAR) agonists show anti-atherosclerotic effects in diabetic mice, independent of metabolic changes. These findings suggest potential benefits for managing diabetic complications and cardiovascular disease.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Cardiovascular Research

Background:

  • Peroxisome proliferator-activated receptors (PPARs) are key regulators of genes involved in diabetic complications.
  • PPAR agonists, including PPARalpha (fenofibrate, gemfibrozil) and PPARgamma (rosiglitazone), are used clinically for managing type 2 diabetes.
  • Diabetic complications, particularly atherosclerosis, represent a significant unmet medical need.

Purpose of the Study:

  • To review the anti-atherosclerotic potential of PPAR agonists.
  • To emphasize recent findings in an animal model of diabetes-associated atherosclerosis.
  • To discuss the clinical implications of PPAR agonist therapy for diabetic cardiovascular complications.

Main Methods:

  • Review of existing literature on PPAR agonists and diabetic atherosclerosis.

Related Experiment Videos

  • Emphasis on studies using the streptozotocin diabetic apolipoprotein E deficient mouse model.
  • Analysis of clinical trial data (PROACTIVE, FIELD) for PPAR agonists.

    • Main Results:

    • PPARalpha agonists (gemfibrozil, fenofibrate) demonstrated anti-atherosclerotic effects in diabetic mice, partly independent of their metabolic actions.
    • The PPARgamma agonist rosiglitazone also showed dose-dependent anti-atherosclerotic effects in the same model.
    • Clinical trials (PROACTIVE, FIELD) provide context for the therapeutic potential.

    Conclusions:

    • PPAR agonists possess significant anti-atherosclerotic properties relevant to diabetic complications.
    • Therapeutic benefits may extend beyond glucose and lipid metabolism control.
    • Further investigation into PPAR agonist mechanisms and clinical utility in diabetic cardiovascular disease is warranted.